MDP vs. FIRE, CPH, OGI, EPI, ICC, RIV, LEAF, CRDL, RX, and HLS
Should you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Supreme Cannabis (FIRE), Cipher Pharmaceuticals (CPH), Organigram (OGI), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), Cardiol Therapeutics (CRDL), BioSyent (RX), and HLS Therapeutics (HLS). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals vs. Its Competitors
Medexus Pharmaceuticals (TSE:MDP) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Supreme Cannabis is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medexus Pharmaceuticals and Medexus Pharmaceuticals both had 1 articles in the media. Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.
Medexus Pharmaceuticals has a net margin of 3.25% compared to Supreme Cannabis' net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 11.07% beat Supreme Cannabis' return on equity.
Medexus Pharmaceuticals currently has a consensus price target of C$5.49, suggesting a potential upside of 93.22%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Medexus Pharmaceuticals is more favorable than Supreme Cannabis.
8.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Medexus Pharmaceuticals beats Supreme Cannabis on 13 of the 13 factors compared between the two stocks.
Get Medexus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medexus Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:MDP) was last updated on 7/16/2025 by MarketBeat.com Staff
Free MDP Stock Alerts